Navigation Links
Ventus Medical Appoints John McCutcheon as President and CEO

- - Also Announces the expansion of PROVENT(R) Sleep Apnea Therapy in Limited US Markets

BELMONT, Calif., April 9 /PRNewswire/ -- Ventus Medical, Inc. a privately-held, medical device company, focused on transforming the Sleep Disordered Breathing market, today announced the appointment of John McCutcheon as President and Chief Executive Officer, effective April 20, 2009. The company also announced that current CEO Jeffrey Nugent will become Executive Chairman.


Mr. McCutcheon joins Ventus Medical from Emphasys Medical where he was President and CEO for the past seven years. Previously, he was head of Sales and Marketing at Perclose, an Abbott Laboratories company and in senior marketing positions at Devices for Vascular Intervention and Baxter Healthcare.

"John is the ideal leader to drive the commercialization of PROVENT Therapy as a novel treatment of obstructive sleep apnea (OSA). He is a proven leader in the medical device field with nearly 25 years of experience," said Mr. Nugent. "Clinical studies have shown that PROVENT Therapy has the potential to improve the quality of life for millions of people around the world who suffer from this disorder," he added. "We are encouraged by the acceptance we are experiencing at both the physician and patient level at the sleep centers where PROVENT Therapy is currently available."

PROVENT Therapy has been cleared by the Food and Drug Administration and is indicated for the treatment of obstructive sleep apnea. PROVENT Therapy is a daily use, prescription device and works across mild, moderate, and severe OSA.

"I am pleased to join Ventus Medical at this exciting time in the Company's development," said John McCutcheon. "PROVENT Therapy is one of the most innovative products to be introduced into the sleep apnea market in years: it is a convenient, discreet and portable solution. We look forward to working closely with the medical community to meet the need for more patient-friendly, effective sleep apnea treatments."

PROVENT Therapy is currently available in a limited number of markets and is in the process of expanding with the assistance and support of professional sleep physicians in the United States.

Also, Ventus Medical has just been awarded the 2009 Medical Design Excellence Award which recognizes those companies responsible for the ground breaking innovations that are changing the face of healthcare.

Ventus Medical's investors include De Novo Ventures, Mohr Davidow Ventures and the Johnson & Johnson Development Corporation. Information on Ventus Medical and PROVENT Therapy can be found on and

SOURCE Ventus Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine ... Jurassic World: The Exhibition, opening in March 2016 at Melbourne Museum in Melbourne, ... tour including several North American tour dates. The Exhibition is based on Universal ...
(Date:11/30/2015)... 30, 2015  Aytu BioScience, Inc. (OTCQB: AYTU), a ... conditions, will present at two upcoming investor conferences. Aytu ... real-time virtual conference, to be held December 3, 2015, ... be held December 2 nd & 3 rd ... and streamed live via webcast. Josh Disbrow ...
(Date:11/30/2015)... Israel , Nov. 30, 2015 ... leading developer of adult stem cell technologies for neurodegenerative diseases, ... has been awarded an additional grant of approximately $735,000 from ... (OCS). This grant, the second this year, brings the total ... $1.8 million (approximately NIS7 million).  ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> Accutest Research Laboratories, ... Contract Research Organization (CRO), has formed ... Cancer Center - Temple Health for ... ,     (Photo: ) , ...
Breaking Biology Technology:
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
Breaking Biology News(10 mins):